

Influence of Genetics on the Degradation of Cannabinoids

Submission date 22/02/2010	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 14/04/2010	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 06/06/2025	Condition category Other	<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Lorenz Theiler

Contact details
University Dept of Anesthesiology and Pain Therapy
Inselspital
Bern
Switzerland
3010
-
ltheiler@med.miami.edu

Additional identifiers

Protocol serial number
THLD2010-1

Study information

Scientific Title
Genetic Influence of CYP2C9 Polymorphism on Pharmacokinetics of intravenously applied d-9-Tetrahydrocannabinol (THC) in Healthy Volunteers

Study objectives

Rate of intravenous applied d-9THC depends on genetically determined CYP2C9, where two polymorphisms (SNP) are known

Ethics approval required

Old ethics approval format

Ethics approval(s)

Cantonal Ethics Committee of Bern approved on the 22nd of February 2010 (ref: KEK-Number 241/09)

Study design

Single centre open label uncontrolled interventional pharmacokinetic study

Primary study design

Interventional

Study type(s)

Other

Health condition(s) or problem(s) studied

Pharmacokinetics, Forensic Medicine, Anesthesiology

Interventions

300 healthy volunteers will be genetically screened for single nucleotide polymorphisms (SNP) in the Cytochrome P450 2C9 (CYP2C9) gene. The three alleles identified for this study will be

1. Wild Type (WT)
2. R144C
3. I359L

30 volunteers will be picked to form 6 groups will be based on the 6 possible allelic combinations; 11 12 13 22 23 33. Each group consists of about 5 people, although there may be some differences due to allelic frequencies. We will not study more than 30 volunteers. If more than 5 persons in a specific group are available from the screened population (that is expected for the WT), than we will randomly choose by computer randomisation.

Participants will receive a single dose of 0.1mg/kg intravenous (IV) THC. Vitals and blood THC levels will be measured continuously for 72 hours.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

d-9-Tetrahydrocannabinol (THC)

Primary outcome(s)

Blood levels of THC and degradation products, assessed by blood sampling at baseline, and 1, 2, 5, 10, 15, 20, 30, 45, 60, 90, 180, 300 Minutes and 24h, 48h after THC injection.

Key secondary outcome(s)

1. Vitals
2. Side effects
3. Well being, assessed by questionnaires filled out at regular intervals as well by Visual Analogue Scale (VAS)
4. Pupillometry will be obtained in a subgroup using standardised techniques

Completion date

01/07/2010

Eligibility

Key inclusion criteria

1. Healthy volunteers
2. 18-65 years old

Participant type(s)

Healthy volunteer

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Upper age limit

65 years

Sex

All

Key exclusion criteria

1. Refusal to participate
2. Does not speak or read German
3. Ongoing smoking status (<3 months since quitting)
4. Extreme nutritive status (BMI outside 16-35)
5. American Society of Anesthesiologists Status Class III and above
6. Suspected coronary heart disease
7. Major heart rhythm disturbances
8. Liver enzymes P450 altering medication
9. Any treated or suspected psychiatric diseases at any time during lifetime. This includes, but is not restricted to schizophrenic disorders, depression, use of heroin, cocaine, LSD, and ongoing use of THC (<1 month since quitting).
10. Pregnant, women will be tested by urine Human Chorionic Gonadotropin (HCG)-stick

Date of first enrolment

01/03/2010

Date of final enrolment

01/07/2010

Locations

Countries of recruitment

Switzerland

Study participating centre

University Dept of Anesthesiology and Pain Therapy

Bern

Switzerland

3010

Sponsor information

Organisation

Inselspital (Switzerland)

ROR

<https://ror.org/01q9sj412>

Funder(s)

Funder type

Hospital/treatment centre

Funder Name

Inselspital (Switzerland) - University Dept of Anesthesiology and Pain Therapy, Departmental Research Fund

Funder Name

Federal Office of Public Health (BAG) (Switzerland) (unrestricted grant)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	Quantification and time course of subjective psychotropic and somatic effects	18/12/2024	19/12/2024	Yes	No
Results article	Effects on pupillary reaction and pupil size	13/05/2025	06/06/2025	Yes	No